APG Asset Management N.V. Lowers Holdings in Humana Inc. $HUM

Key Points

• APG Asset Management N.V. reduced its stake in Humana Inc. by 5.4%, selling 4,683 shares, and now holds approximately 0.07% of the company, valued at $19,975,000.
• In recent analyst reports, firms such as Wells Fargo and Bank of America adjusted their price targets on Humana's stock, indicating a consensus price target of $283.29 and a mixed rating of 'Hold' and 'Buy' from analysts.
• Humana announced a quarterly dividend of $0.885 per share, representing an annualized yield of 1.2%, with a payout ratio of 27.17%.

APG Asset Management N.V. trimmed its stake in Humana Inc. (NYSE:HUM - Free Report) by 5.4% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 81,546 shares of the insurance provider's stock after selling 4,683 shares during the period. APG Asset Management N.V. owned 0.07% of Humana worth $19,975,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Cary Street Partners Investment Advisory LLC grew its position in shares of Humana by 63.9% in the 1st quarter. Cary Street Partners Investment Advisory LLC now owns 118 shares of the insurance provider's stock worth $31,000 after buying an additional 46 shares during the period. Riverview Trust Co bought a new stake in shares of Humana in the 1st quarter worth $34,000. Garde Capital Inc. purchased a new stake in shares of Humana during the first quarter valued at $36,000. Zions Bancorporation National Association UT purchased a new stake in shares of Humana during the first quarter valued at $37,000. Finally, Whipplewood Advisors LLC boosted its position in shares of Humana by 639.1% during the first quarter. Whipplewood Advisors LLC now owns 170 shares of the insurance provider's stock valued at $45,000 after buying an additional 147 shares during the last quarter. 92.38% of the stock is owned by hedge funds and other institutional investors.

Humana Stock Up 0.2%

HUM stock traded up $0.73 on Thursday, hitting $297.99. 997,492 shares of the company's stock were exchanged, compared to its average volume of 1,708,264. Humana Inc. has a 12-month low of $206.87 and a 12-month high of $382.72. The firm has a 50 day moving average price of $252.05 and a two-hundred day moving average price of $254.08. The company has a debt-to-equity ratio of 0.69, a quick ratio of 1.95 and a current ratio of 1.95. The stock has a market cap of $35.84 billion, a P/E ratio of 22.87, a price-to-earnings-growth ratio of 1.76 and a beta of 0.44.

Humana (NYSE:HUM - Get Free Report) last issued its earnings results on Wednesday, July 30th. The insurance provider reported $6.27 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $6.32 by ($0.05). The firm had revenue of $32.39 billion during the quarter, compared to analysts' expectations of $31.85 billion. Humana had a return on equity of 13.67% and a net margin of 1.28%.The business's revenue was up 9.6% on a year-over-year basis. During the same quarter last year, the business earned $6.96 EPS. Humana has set its FY 2025 guidance at 17.000- EPS. As a group, equities research analysts expect that Humana Inc. will post 16.47 EPS for the current fiscal year.

Humana Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, October 31st. Investors of record on Friday, September 26th will be paid a $0.885 dividend. The ex-dividend date is Friday, September 26th. This represents a $3.54 dividend on an annualized basis and a yield of 1.2%. Humana's dividend payout ratio (DPR) is 27.17%.

Analyst Upgrades and Downgrades

A number of analysts recently commented on the company. Piper Sandler reduced their price objective on Humana from $288.00 to $272.00 and set a "neutral" rating for the company in a research report on Thursday, July 31st. Bank of America cut their price target on Humana from $320.00 to $260.00 and set a "neutral" rating for the company in a research note on Tuesday, June 17th. Robert W. Baird decreased their price target on shares of Humana from $300.00 to $297.00 and set a "neutral" rating on the stock in a research note on Friday, July 25th. Wall Street Zen cut shares of Humana from a "buy" rating to a "hold" rating in a research note on Saturday, August 2nd. Finally, Barclays set a $275.00 price objective on shares of Humana and gave the stock an "equal weight" rating in a research note on Thursday, July 31st. Seven investment analysts have rated the stock with a Buy rating and sixteen have issued a Hold rating to the company. According to MarketBeat, the stock has an average rating of "Hold" and a consensus target price of $283.29.

About Humana

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.